Avanir Settles With Wockhardt Over Nuedexta, Generic Entry

Avanir Pharmaceuticals said Sept. 6 it has entered into a settlement agreement granting Wockhardt the right to sell a generic of Nuedexta before its last protective patent expires on Aug. 15, 2026. The accord grants Wockhardt the right to begin selling a generic version of Nuedexta (dextromethorphan hydrobromide and quinidine sulfate 20 mg/10 mg) on July 30, 2026, or “earlier under certain circumstances.”
Generic Line